转自：北京日报客户端 新版医保目录已进入实质性落地阶段。1月8日，北京商报记者注意到，包括替妥尤单抗N01注射液、夫 那奇珠单抗注射液在内的多款新增创新药，已在多地医院纷纷开出医保首方。这标志着患者使用这些高 价创新药的实际门槛正在快速降低，新版目录的惠民效应开始显现。 本次医保目录调整不仅新增了114种药品，更首次同步推出《商业健康保险创新药品目录（2025 年）》，通过"基本医保+商保"的双重保障，为肿瘤、罕见病等领域19种高值药品开辟了可及的支付通 路，医保支付体系向多层次保障的实质性转型迈出关键一步，创新药企也迎来了加速商业化放量的重要 节点。 从上市到开出医保首方不足一年 创新药迅速落地医保，是新版医保目录对具有高临床价值"真创新"支持力度加大的直接体现。本次调整 中，新版医保目录与商保创新药目录共纳入独家品种124个。 其中，备受关注的替妥尤单抗N01注射液是国内首款用于治疗甲状腺眼病的靶向药物，从2025年3月上 市，到开出医保首方，用时不到一年，填补了我国该领域近70年的治疗空白。 夫那奇珠单抗注射液则是用于治疗银屑病的生物制剂1类创新药，由恒瑞医药自主研发。恒瑞医药在本 次医保目录调整中被视 ...

新版医保目录已进入实质性落地阶段。1月8日，北京商报记者注意到，包括替妥尤单抗N01注射液、夫 那奇珠单抗注射液在内的多款新增创新药，已在多地医院纷纷开出医保首方。这标志着患者使用这些高 价创新药的实际门槛正在快速降低，新版目录的惠民效应开始显现。 倒逼药企研发策略转向真创新 本次医保目录调整不仅新增了114种药品，更首次同步推出《商业健康保险创新药品目录（2025 年）》，通过"基本医保+商保"的双重保障，为肿瘤、罕见病等领域19种高值药品开辟了可及的支付通 路，医保支付体系向多层次保障的实质性转型迈出关键一步，创新药企也迎来了加速商业化放量的重要 节点。 不到一年开出医保首方 创新药迅速落地医保，是新版医保目录对具有高临床价值"真创新"支持力度加大的直接体现。本次调整 中，新版医保目录与商保创新药目录共纳入独家品种124个。 其中，备受关注的替妥尤单抗N01注射液是国内首款用于治疗甲状腺眼病的靶向药物，从2025年3月上 市，到开出医保首方，用时不到一年，填补了我国该领域近70年的治疗空白。 夫那奇珠单抗注射液则是用于治疗银屑病的生物制剂1类创新药，由恒瑞医药自主研发。恒瑞医药在本 次医保目录调整中被视为 ...

为保障政策落地见效，日前省医保局联合省人社厅印发通知，明确全省定点医疗机构应在2026年2 月底前召开专题药事会，优先配备谈判药品且不受"一品两规"限制，严禁以总额控制、药占比等为由限 制合理用药。 结合特药管理实际，陕西同步联动调整特药管理范围，新增59种、调出6种后，特药管理品种增至 337种。同时，通过强化特药外配处方流转监管，让特药保障更规范、更高效。 作为此次政策的一大创新，国家医保局首设的商保创新药品目录备受关注。该目录纳入的19种药物 均为超出基本医保保障定位、暂未纳入医保目录，但创新程度高、临床价值突出、患者获益明显的创新 药物，推荐商业健康保险、医疗互助等多层次保障体系参考使用。这一举措丰富了保障供给，推动商保 与基本医保错位发展，为构建全方位医疗保障体系奠定基础。 "我们将加强政策培训与宣传解读，主动回应社会关切，确保新版'双目录'平稳落地，让政策红利 真正直达患者，切实减轻群众就医负担。"省医保局相关负责人说。（记者：李旭佳） 1月4日，记者从省医保局获悉：日前，《国家基本医疗保险、生育保险和工伤保险药品目录（2025 年）》以及《商业健康保险创新药品目录（2025年）》已在陕西落地执行 ...

Core Viewpoint - The performance of innovative drug IPOs, particularly in the GLP-1 sector, continues to rise, with Silverno Pharmaceuticals achieving a significant market valuation and investor interest upon its listing [1] Group 1: Company Overview - Silverno Pharmaceuticals listed on the Hong Kong Stock Exchange on August 15, with an intraday increase of up to 300%, ultimately closing with a 200% rise and a market capitalization exceeding 26 billion [1] - The company has successfully commercialized its self-developed GLP-1 drug, Isupaglutide α, for the treatment of type 2 diabetes, generating nearly 40 million in sales by the end of May [1][10] - The company has a strong product pipeline, with Isupaglutide α showing a half-life of 204 hours, which is longer than competitors' products, potentially allowing for reduced dosing frequency [4][12] Group 2: Market Context - The GLP-1 market is experiencing a shift towards long-acting formulations, with projections indicating that by 2024, long-acting GLP-1 products will capture 96.5% of the global market and 86.9% in China [4] - The competitive landscape is intensifying, with numerous companies, including both domestic and international players, developing GLP-1 drugs for weight loss indications, leading to a crowded market [8][11] Group 3: Clinical Development - Isupaglutide α has shown promising results in clinical trials, with an average weight reduction of 8.13% after four weeks of treatment, compared to 0.79% in the placebo group [5][6] - The drug is currently undergoing IIb/III clinical trials, with results expected by the end of next year [7] Group 4: Sales and Marketing Strategy - Silverno Pharmaceuticals has established a 15-member sales team with an average of 20 years of experience in metabolic diseases, and has emphasized online sales channels to reach consumers [8][10] - The company achieved notable sales rankings during the "618" shopping festival, indicating strong market penetration [9] Group 5: Industry Challenges - The GLP-1 weight loss market is facing scrutiny, with recent reports indicating that over 70% of GLP-1 drug users have discontinued use in the past two years, highlighting challenges in user retention [12] - The competitive dynamics are shifting, as major players like Pfizer have halted GLP-1 pipeline developments due to market assessments, raising concerns about future profitability in the sector [11][12]